Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer

Published:2021-05-31 Issue:5 Volume:44 Page:363-373
ISSN:0219-1032
Container-title:Molecules and Cells
language:en
Short-container-title:Mol.Cells

Author:

Lee Yong Jun¹²^ORCID,Lee Jii Bum¹³²^ORCID,Ha Sang-Jun⁴^ORCID,Kim Hye Ryun¹^ORCID

Affiliation:

1. Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul 03722, Korea

2. These authors contributed equally to this work.

3. Division of Hemato-oncology, Wonju Severance Christian Hospital, Yonsei University College of Medicine, Wonju 26426, Korea

4. Department of Biochemistry, College of Life Science & Biotechnology, Yonsei University, Seoul 03722, Korea

Funder

Ministry of Science and ICT, South Korea

Publisher

Korean Society for Molecular and Cellular Biology

Subject

Cell Biology,Molecular Biology,General Medicine

Link

http://pdf.medrang.co.kr/KSMCB/2021/044/KSMCB044-05-11.pdf

Reference75 articles.

1. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer

2. Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs)

3. Epigenetic mechanisms of tumor resistance to immunotherapy

4. In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy

5. Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strong capacity of differentiated PD-L1 CAR-modified UCB-CD34+ cells and PD-L1 CAR-modified UCB-CD34+-derived NK cells in killing target cells and restoration of the anti-tumor function of PD-1-high exhausted T Cells;Stem Cell Research & Therapy;2024-08-13

2. CDKN2 expression is a potential biomarker for T cell exhaustion in hepatocellular carcinoma;BMB Reports;2024-02-20

3. Platinum-based neoadjuvant chemotherapy upregulates STING/IFN pathway expression and promotes TILs infiltration in NSCLC;Frontiers in Oncology;2024-02-15

4. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial;Nature Medicine;2024-02-13

5. Novel technologies for applying immune checkpoint blockers;International Review of Cell and Molecular Biology;2024